Across TCGA pan-cancer cohorts, PTRHD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTRHD1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTRHD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTRHD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where PTRHD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.527	0.826	.013	13	view →
CCRCC	DFS	Quartile	All	0.966	0.836	.027	4	view →
LUAD	DFS	Median	II,III,IV	0.341	0.669	.024	4	view →
UCEC	DFS	Quartile	All	1.000	0.809	.011	4	view →
GBM	DFS	Quartile	All	0.542	0.831	.010	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PTRHD1 tumor-vs-normal RNA expression · all PTRHD1 data types